Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

PURPOSE Activation of the KIT tyrosine kinase by somatic mutation has been documented in a number of human malignancies, including gastrointestinal stromal tumor (GIST), seminoma, acute myelogenous leukemia (AML), and mastocytosis. In addition, paracrine or autocrine activation of this kinase has been postulated in numerous other malignancies, including small-cell lung cancer and ovarian cancer. In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies. MATERIALS AND METHODS Studies were identified through a MEDLINE search, review of bibliographies of relevant articles, and review of abstracts from national meetings. RESULTS Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clinical trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia. The role of KIT inhibitors in treating KIT-positive malignancies is reviewed. CONCLUSION Targeted therapy to inhibit the kinase activity of KIT is a rational approach to the treatment of KIT-positive malignancies. Two key factors are the potency of a given inhibitor and the relative contribution of KIT activation to the growth of the tumor. Given our current understanding of KIT activity in human malignancy, the best candidate diseases for treatment with KIT inhibitors are GIST, mastocytosis, seminoma and possibly some cases of AML. Additionally, KIT inhibitors may play an adjunctive role in diseases such as small-cell lung cancer, in which KIT activation is secondary to ligand binding rather than an acquired mutation.

[1]  E. Russell.  Hereditary anemias of the mouse: a review for geneticists. , 1979, Advances in genetics.

[2]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[3]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[4]  A. Bernstein,et al.  Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.

[5]  P. Leder,et al.  The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus , 1990, Cell.

[6]  K. Manova,et al.  Gonadal expression of c-kit encoded at the W locus of the mouse. , 1990, Development.

[7]  P. Quesenberry,et al.  Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA+Lin- murine hematopoietic progenitors. , 1991, Experimental hematology.

[8]  S. Lev,et al.  A specific combination of substrates is involved in signal transduction by the kit‐encoded receptor. , 1991, The EMBO journal.

[9]  K. Sakamaki,et al.  Effect of the W mutation, for white belly spot, on testicular germ cell differentiation in mice. , 1991, Journal of reproduction and fertility.

[10]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[11]  R. Ueda,et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. , 1991, Cancer research.

[12]  C. Brannan,et al.  Requirement for mast cell growth factor for primordial germ cell survival in culture , 1991, Nature.

[13]  R. Spritz,et al.  Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.

[15]  M. Tsai,et al.  Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Enjoji,et al.  A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors , 1992, Cancer.

[17]  R. Fleischman.  Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene. , 1992, The Journal of clinical investigation.

[18]  I. Bernstein,et al.  Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. , 1992, Blood.

[19]  A. Ullrich,et al.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. , 1992, Cancer research.

[20]  K. Zsebo,et al.  Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. , 1992, Blood.

[21]  C. Ma,et al.  Immunohistologic characterization of gastrointestinal stromal tumors: a study of 82 cases compared with 11 cases of leiomyomas. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[22]  T. Tsukamoto,et al.  Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. , 1993, Cancer research.

[23]  J. Cortes,et al.  Chronic myelogenous leukemia. , 1994, Current opinion in oncology.

[24]  E. R. Meyts,et al.  Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours , 1994 .

[25]  R. Seeger,et al.  Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group , 1994 .

[26]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. , 1994 .

[28]  G. Krystal,et al.  Coexpression of the c-kit and stem cell factor genes in breast carcinomas. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  H. Kitayama,et al.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. , 1995, Blood.

[30]  R. Bachvarova,et al.  Kit ligand mediates survival of type a spermatogonia and dividing spermatocytes in postnatal mouse testes , 1995, Molecular reproduction and development.

[31]  D. Franquemont.  Differentiation and risk assessment of gastrointestinal stromal tumors. , 1995, American journal of clinical pathology.

[32]  M. Miettinen,et al.  Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. , 1995, The American journal of surgical pathology.

[33]  G. Giaccone,et al.  Differential expression of the c‐kit proto‐oncogene in germ cell tumours , 1995, The Journal of pathology.

[34]  A. Hakura,et al.  An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis. , 1995, Oncogene.

[35]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[36]  L. Ashman,et al.  Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. , 1996, Leukemia.

[37]  H. Egami,et al.  Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. , 1996, British Journal of Cancer.

[38]  Y. Matsuzawa,et al.  Role of Aspartic Acid 814 in the Function and Expression of c-kit Receptor Tyrosine Kinase (*) , 1996, The Journal of Biological Chemistry.

[39]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Suster.  Gastrointestinal stromal tumors. , 1996, Seminars in diagnostic pathology.

[41]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[42]  M. Ueda,et al.  c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi , 1996, Melanoma research.

[43]  W. Vainchenker,et al.  A new c‐kit mutation in a case of aggressive mast cell disease , 1997, British journal of haematology.

[44]  D. Elder,et al.  Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[45]  S. Hirota,et al.  Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats , 1997, Cell and Tissue Research.

[46]  G. Basso,et al.  Stem cell factor suppresses apoptosis in neuroblastoma cell lines. , 1997, Experimental hematology.

[47]  R. DiPaola,et al.  Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. , 1997, Cancer gene therapy.

[48]  N. Sepp,et al.  Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. , 1998, The Journal of investigative dermatology.

[49]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[50]  D. DiMaio,et al.  A single amino acid substitution in a WW‐like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation , 1998, The EMBO journal.

[51]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[52]  D. Arber,et al.  Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. , 1998, Human pathology.

[53]  H. Kawasaki,et al.  Serum soluble c‐kit receptor and expression of c‐kit protein and mRNA in acute myeloid leukemia , 1998, European journal of haematology.

[54]  K. Welte,et al.  Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells , 1998, Leukemia.

[55]  Alberto L. Horenstein,et al.  c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. , 1998, Blood.

[56]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[57]  R. Cairoli,et al.  In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. , 1998, Blood cells, molecules & diseases.

[58]  R. Y. Chow,et al.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. , 1999, The Biochemical journal.

[59]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Sandlow,et al.  Migration and ultrastructural localization of the c-kit receptor protein in spermatogenic cells and spermatozoa of the mouse. , 1999, The Journal of urology.

[61]  S. Fosså,et al.  Spermatocytic seminoma as compared to classical seminoma: An immunohistochemical and DNA flow cytometric study , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[62]  J. Reilly,et al.  c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia , 1999, British journal of haematology.

[63]  L. Regan,et al.  Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.

[64]  C. Moskaluk,et al.  KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[65]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[66]  L. Sobin,et al.  Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. , 1999, The American journal of surgical pathology.

[67]  Edvardsson,et al.  Expression of c‐kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours , 1999, Histopathology.

[68]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[69]  T. Kaisho,et al.  Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. , 1999, Blood.

[70]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[71]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[72]  T. Hunter,et al.  Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility , 2000, Nature Genetics.

[73]  M. Skinner,et al.  Expression and Action of Kit Ligand/Stem Cell Factor in Normal Human and Bovine Ovarian Surface Epithelium and Ovarian Cancer1 , 2000, Biology of reproduction.

[74]  L. Sobin,et al.  Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. , 2000, The American journal of pathology.

[75]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[76]  M. Wasik,et al.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. , 2000, The American journal of pathology.

[77]  S. Hirota,et al.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[78]  L. Ellis,et al.  Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. , 2000, Anti-cancer drug design.

[79]  B. Longley,et al.  A proposed classification of mastocytosis incorporating molecular genetics. , 2000, Hematology/oncology clinics of North America.

[80]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[81]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[82]  T. Hongyo,et al.  Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. , 2000, Cancer research.

[83]  B. Vanderhyden,et al.  Lack of expression of c‐KIT in ovarian cancers is associated with poor prognosis , 2000, International journal of cancer.

[84]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  L. Sobin,et al.  Gastrointestinal Stromal Tumors and Leiomyosarcomas in the Colon: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases , 2000, The American journal of surgical pathology.

[86]  C. Sette,et al.  The role of stem cell factor and of alternative c-kit gene products in the establishment, maintenance and function of germ cells. , 2000, The International journal of developmental biology.

[87]  J. Lasota,et al.  KIT Expression in Angiosarcomas and Fetal Endothelial Cells: Lack of Mutations of Exon 11 and Exon 17 of C-kit , 2000, Modern Pathology.

[88]  M. Heinrich,et al.  STI 571 inhibits the kinase activity of wild type and juxtamembrane C-kit mutants but not the exon 17 D816V mutation associated with mastocytosis , 2000 .

[89]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[90]  Y. Natkunam,et al.  Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. , 2000, The American journal of surgical pathology.

[91]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[92]  Y. Jeng,et al.  Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. , 2000, Cancer letters.

[93]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[94]  G. Rosen,et al.  Recurrent gastrointestinal stromal sarcomas. , 2000, Surgical oncology.

[95]  P. Peterlongo,et al.  RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. , 2000, Human molecular genetics.

[96]  G. Mcmahon,et al.  Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. , 2000, The Journal of investigative dermatology.

[97]  R. Cairoli,et al.  Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. , 2000, Cancer genetics and cytogenetics.

[98]  C. Cordon-Cardo,et al.  Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. , 2000, Histology and Histopathology.

[99]  David A. Williams,et al.  Genetic and Biochemical Evidence That Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates in Vivo , 2000, The Journal of experimental medicine.

[100]  Cherrington,et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.

[101]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[102]  J. Cherrington,et al.  The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. , 2001, Blood.

[103]  B. Druker,et al.  Chronic myeloid leukemia: current treatment options. , 2001, Blood.

[104]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[105]  J. Lewin,et al.  A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer , 2001 .

[106]  A. Haman,et al.  Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. , 2001, Cancer research.

[107]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[108]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[109]  S. Honsawek,et al.  Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. , 2001, Cancer research.

[110]  A. Kuraishi,et al.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.

[111]  T. Nishida,et al.  Gain‐of‐function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours , 2001, The Journal of pathology.

[112]  W. Berdel,et al.  Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. , 2001, Blood.

[113]  L. Elmore,et al.  Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. , 2001, Archives of pathology & laboratory medicine.

[114]  569 A phase I and pharmacokinetic study of oral administration of SU5416 in patients with advanced solid tumors , 2003 .

[115]  Olivier Hermine,et al.  Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms , 2003, Oncogene.

[116]  F. Galibert,et al.  Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains , 1995, Journal of Molecular Evolution.